Dahlgren Capital has announced a strategic investment of EUR 6.6 million (USD 7.3 million) in Danish medtech company Brainreader, leading a financing round alongside continued support from existing shareholder Investo Capital. This investment marks a significant step in Dahlgren Capital’s commitment to supporting high-impact technology companies with global growth ambitions.

Brainreader is a pioneering medtech innovator dedicated to advancing clinical neuroscience through AI-powered diagnostic solutions. The company’s flagship product, Neuroreader, is both CE-marked and FDA-cleared, enabling radiologists and neurologists to perform fast, precise volumetric analysis of brain MRI scans. Neuroreader is used in clinical practice to aid in the diagnosis and monitoring of neurological conditions such as Alzheimer’s disease, traumatic brain injury, and other neurodegenerative disorders. The technology integrates seamlessly into existing clinical workflows, helping healthcare professionals detect subtle changes in brain structure with greater accuracy and efficiency.

“This investment allows us to expand faster and reach more clinics worldwide,” says Mads Fiig, CEO of Brainreader. “We’re proud to have the backing of Dahlgren Capital and Investo Capital, whose combined experience in AI and growth-stage companies will be instrumental in our next phase.”

“Brainreader is building a category-defining solution in AI-enabled brain diagnostics,” says Peter Dahlgren, CEO of Dahlgren Capital. “We are excited to support the team as they scale globally and bring cutting-edge neuroimaging tools to more clinicians and patients.”

The capital injection will accelerate Brainreader’s commercial expansion, particularly in the U.S. healthcare market, and support the continued development of new features and clinical applications. In the U.S., the adoption of CPT codes for brain volumetry is creating new reimbursement pathways, while compliance with Medical Device Regulation (MDR) in the EU enables broader clinical use of AI-powered imaging tools across member states.

“We see strong tailwinds for AI in neuroimaging,” adds Thor Birkmand, Chairman of Brainreader and partner at Investo Capital. “With this funding and the addition of Dahlgren Capital as an active owner, Brainreader is well-equipped to lead this transformation.”

This investment aligns with Dahlgren Capital’s strategy to back and support innovative technology companies in AI and automation, and reflects its mission to drive long-term value creation for entrepreneurs, portfolio companies, and investors.